Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity - PubMed
4 hours ago
- #Cancer Immunotherapy
- #Glioblastoma Treatment
- #CAR T Cells
- A new CAR T cell blend targets both PDPN and GD2 to address glioblastoma's high heterogeneity.
- The blend showed strong anti-tumor activity in vitro against cell lines and patient-derived organoids, inducing higher apoptosis than single-target CAR Ts.
- In vivo, locoregional administration of the CAR T blend significantly improved survival and achieved cures in most mice, unlike single-antigen therapies.
- PDPN and GD2 were consistently expressed across all patient-derived organoids, making them reliable targets for targeting heterogeneous GBM.
- The study suggests this novel blend could overcome limitations of single-antigen CAR T cell therapies for treating glioblastoma.